Atypical antipsychotics can work quickly in mood disorders, but their long-term risks give us pause. When is it safe to discontinue them? The answer, it turns out, depends on whether we look to industry-supported or industry-independent trials.

Two devices are available for transcranial magnetic stimulation (TMS). Neurostar came first with the figure-8 coil, which is now off-patent, while Brainsway’s H-coil which claims to reach deeper into the cerebral cortex. See how they compare in the first head-to-head controlled trial, undertaken without industry support.

FDA Clears the Path for Magic Mushrooms. Psilocybin, the psychedelic compound in magic mushrooms, was fast-tracked by the FDA for major depression in November 2019.

After reading these articles, you should be able to…

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit.

Quick hits on what you’ll find in this issue.

“I think I have ADHD” is a common complaint of psychiatric patients. Just about every disorder in the DSM can cause symptoms of ADHD, as can a host of medical problems. In this article we’ll show you how to sort through the possibilities.

Vitamins like B12 and folate have mental benefits, but what happens when you combine dozens of vitamins and nutrients in a single pill? We were skeptical, but the studies were positive, so we invited Julia Rucklidge to explain how these “micronutrients” work in ADHD, depression, autism, and general mental health.

In this issue, we tackle one of the vexing problems in outpatient psychiatry: adults who present with ADHD.

From the Oval Office to the college dorm, stimulants are often used as performance-enhancing drugs. The ethics of this practice are questionable, but so is the science. New research suggests their pro-cognitive effects are mild at best and come with an unexpected cost on working memory.